Assessing Ascentage Pharma Group International’s Valuation After AACR 2026 Preclinical Oncology Selections

Ascentage Pharma Group International (SEHK:6855) has drawn fresh attention after announcing that four abstracts from its preclinical oncology programs will be presented at the AACR Annual Meeting 2026, highlighting several pipeline drug candidates.

See our latest analysis for Ascentage Pharma Group International.

At a share price of HK$47.46, Ascentage Pharma Group International has seen short term share price momentum pick up slightly. The 1 year total shareholder return of 22.64% and 3 year total shareholder return of 106.35% point to much stronger gains over time, suggesting recent AACR related interest is arriving after a longer period of significant value creation for holders.

If oncology news like this has your attention, it could be a good moment to see what else is emerging in the sector through our screener of 126 healthcare AI stocks.

With the shares trading at HK$47.46 and an implied intrinsic discount of 84%, plus a large gap to the current analyst price target, investors have to ask: is there genuine value here or is future growth already priced in?

Most Popular Narrative: 47.9% Undervalued

With Ascentage Pharma Group International closing at HK$47.46 against a narrative fair value of HK$91.17, the current price sits well below that central estimate, and the gap rests on a detailed set of clinical and financial assumptions.

The company remains fundamentally vulnerable due to its heavy reliance on a development-stage pipeline in highly competitive oncology segments, where clinical failure or regulatory delay, compounded by industry-wide scrutiny of trial design, could halt new product launches and trigger significant drops in projected revenue and net margins.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue path and margin shift would need to play out for that higher fair value to hold? The narrative leans on specific growth assumptions, a sharp profitability swing and a premium future earnings multiple that is usually reserved for the strongest names in the sector, all tied together under a single discount rate and time frame that you can scrutinise for yourself.

Result: Fair Value of HK$91.17 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, rapid uptake of Olverembatinib or stronger than expected Takeda partnership cash flows could challenge the bearish narrative and support higher confidence in the HK$91.17 fair value.

Find out about the key risks to this Ascentage Pharma Group International narrative.

Another View: Market Ratios Flash A Different Signal

While the SWS DCF model points to Ascentage Pharma Group International trading at an 83.5% discount to its future cash flow value, the current P/S of 39.2x tells a very different story. It sits far above the Hong Kong Biotechs average of 13.6x, the peer average of 11.6x and a fair ratio of 14.5x that the market could move towards. Which signal do you put more weight on?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals like these can create plenty of noise, so move quickly to review the full picture for yourself, including the 3 key rewards and 1 important warning sign.

Ready to uncover more opportunities?

If you stop here, you only see one piece of the puzzle. Broaden your watchlist with fresh ideas that match different portfolio goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com